Susan A Arnold, Amanda R Taylor, Katherine Hansen, Vijay Agarwal, Walter C Low, G Elizabeth Pluhar
{"title":"Immunotherapy yields breed-specific worst survival outcomes among three investigated therapies in French bulldogs with high-grade glioma.","authors":"Susan A Arnold, Amanda R Taylor, Katherine Hansen, Vijay Agarwal, Walter C Low, G Elizabeth Pluhar","doi":"10.3389/fvets.2025.1532439","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>French bulldogs are one of the most popular dog breeds in the United States and are also among breeds with the highest risk for developing high-grade glioma (HGG). With limited treatment options and high translational value for studying canine HGG to advance understanding of human glioblastoma (GB), a variety of novel treatment options have been investigated. In other forms of cancer, immunotherapy has shown promising results, garnering interest in the treatment of HGG. Yet, when an immunotherapy-based clinical trial was conducted, a marked survival disparity in French bulldog patients compared to other breeds was observed.</p><p><strong>Methods: </strong>This retrospective, multi-institutional study was conducted to examine survival outcomes in immunotherapy-treated French bulldogs compared to closely related breeds, and to French bulldogs treated with several other treatment modalities.</p><p><strong>Results: </strong>French bulldogs treated with immunotherapy experienced significantly shorter overall survival (OS) than boxers and Boston terriers (132 vs. 221 days, respectively). French bulldogs treated with immunotherapy had no significant difference in OS compared to French bulldogs treated palliatively, whereas dogs treated with either a novel therapy involving sonodynamic therapy or stereotactic radiation therapy had significantly longer OS.</p><p><strong>Discussion: </strong>This study provides evidence for an immunotherapy-resistant form of HGG in French bulldogs, suggesting that the breed harbors key molecular differences affecting the tumor and tumor-immune microenvironment and subsequent poor response to treatment.</p>","PeriodicalId":12772,"journal":{"name":"Frontiers in Veterinary Science","volume":"12 ","pages":"1532439"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961989/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Veterinary Science","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.3389/fvets.2025.1532439","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: French bulldogs are one of the most popular dog breeds in the United States and are also among breeds with the highest risk for developing high-grade glioma (HGG). With limited treatment options and high translational value for studying canine HGG to advance understanding of human glioblastoma (GB), a variety of novel treatment options have been investigated. In other forms of cancer, immunotherapy has shown promising results, garnering interest in the treatment of HGG. Yet, when an immunotherapy-based clinical trial was conducted, a marked survival disparity in French bulldog patients compared to other breeds was observed.
Methods: This retrospective, multi-institutional study was conducted to examine survival outcomes in immunotherapy-treated French bulldogs compared to closely related breeds, and to French bulldogs treated with several other treatment modalities.
Results: French bulldogs treated with immunotherapy experienced significantly shorter overall survival (OS) than boxers and Boston terriers (132 vs. 221 days, respectively). French bulldogs treated with immunotherapy had no significant difference in OS compared to French bulldogs treated palliatively, whereas dogs treated with either a novel therapy involving sonodynamic therapy or stereotactic radiation therapy had significantly longer OS.
Discussion: This study provides evidence for an immunotherapy-resistant form of HGG in French bulldogs, suggesting that the breed harbors key molecular differences affecting the tumor and tumor-immune microenvironment and subsequent poor response to treatment.
期刊介绍：
Frontiers in Veterinary Science is a global, peer-reviewed, Open Access journal that bridges animal and human health, brings a comparative approach to medical and surgical challenges, and advances innovative biotechnology and therapy.
Veterinary research today is interdisciplinary, collaborative, and socially relevant, transforming how we understand and investigate animal health and disease. Fundamental research in emerging infectious diseases, predictive genomics, stem cell therapy, and translational modelling is grounded within the integrative social context of public and environmental health, wildlife conservation, novel biomarkers, societal well-being, and cutting-edge clinical practice and specialization. Frontiers in Veterinary Science brings a 21st-century approach—networked, collaborative, and Open Access—to communicate this progress and innovation to both the specialist and to the wider audience of readers in the field.
Frontiers in Veterinary Science publishes articles on outstanding discoveries across a wide spectrum of translational, foundational, and clinical research. The journal''s mission is to bring all relevant veterinary sciences together on a single platform with the goal of improving animal and human health.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
